PT  - JOURNAL ARTICLE
AU  - Yuhua Fan
AU  - Jian Yu
AU  - Hongbing Chen
AU  - Jian Zhang
AU  - Jiangang Duan
AU  - Dapeng Mo
AU  - Wenhao Zhu
AU  - Bo Wang
AU  - Fubing Ouyang
AU  - Yicong Chen
AU  - Linfang Lan
AU  - Jinsheng Zeng
ED  - ,
TI  - Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis
AID  - 10.1136/svn-2020-000358
DP  - 2020 Jun 01
TA  - Stroke and Vascular Neurology
PG  - 152--158
VI  - 5
IP  - 2
4099  - http://svn.bmj.com/content/5/2/152.short
4100  - http://svn.bmj.com/content/5/2/152.full
SO  - Stroke Vasc Neurol2020 Jun 01; 5
AB  - Aim Cerebral venous sinus thrombosis (CVST) is a less common cerebrovascular disease that predominantly affects young patients. The incidence of CVST is 2–5/10 000 000/year, accounting for 0.5%–1% of all stroke. To reduce mortality and morbidity associated with CVST, Chinese Stroke Association commissioned the authors to write the current guideline on the management of CVST.Methods PubMed (MEDLINE), CNKI and Wanfang database were searched for studies related to CVST from 1 January 1990 to 31 July 2019. Data were synthesised by evidence tables. Each recommendation was fully discussed by the writing group members and reviewed by Chinese Stroke Association Stroke Fellow Committees. Levels of evidence grading algorithm of Chinese Stroke Association was used to grade each recommendation.Results This guideline mainly focuses on the diagnostic evaluation, therapeutic strategies and secondary prevention of CVST. CT/CTV and MRI/MRV are recommended in the initial imaging evaluation of patients with suspected CVST. Anticoagulation therapy with low-molecular weight heparin should be initiated in patients with CVST immediately. After the acute stage, warfarin is recommended for 3–6 months to prevent the recurrence of CVST and other venous thromboembolic events.Conclusions The guideline summarises the current evidence regarding the management of CVST, and provides references for diagnosis, treatment and secondary prevention of CVST in China.